Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
8.62
+0.02 (0.29%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Theravance Biopharma stock have an average target of 11.33, with a low estimate of 9.00 and a high estimate of 15. The average target predicts an increase of 31.44% from the current stock price of 8.62.
Analyst Consensus: Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for Theravance Biopharma stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +74.01% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +74.01% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +74.01% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $15 | Strong Buy | Maintains | $20 → $15 | +74.01% | Aug 6, 2024 |
| TD Cowen | TD Cowen | Hold Maintains $10 → $9 | Hold | Maintains | $10 → $9 | +4.41% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
97.27M
from 64.38M
Increased by 51.09%
Revenue Next Year
88.43M
from 97.27M
Decreased by -9.09%
EPS This Year
-0.34
from -1.15
EPS Next Year
-1.03
from -0.34
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.9M | 113.1M | 134.8M | ||
| Avg | 97.3M | 88.4M | 109.7M | ||
| Low | 91.1M | 69.0M | 77.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.2% | 16.3% | 52.5% | ||
| Avg | 51.1% | -9.1% | 24.0% | ||
| Low | 41.6% | -29.1% | -12.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | -0.86 | -0.23 | ||
| Avg | -0.34 | -1.03 | -0.59 | ||
| Low | -0.48 | -1.31 | -0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.